^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
177Lu-LNC1003
i
Other names: 177Lu-LNC1003, 177Lu-PSMA-EB-01
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Dongcheng Pharma
Drug class:
Ionizing radiation emitter, PSMA inhibitor
Related drugs:
4ms
The Safety and Dosimetry Study of 177Lu-LNC1003 Injection (clinicaltrials.gov)
P1, N=12, Not yet recruiting, Yantai LNC Biotechnology Singapore PTE. LTD. | Initiation date: May 2024 --> May 2025
Trial initiation date • Metastases
|
177Lu-LNC1003
4ms
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
P=N/A, N=9, Recruiting, Peking Union Medical College Hospital | Trial completion date: Nov 2023 --> Nov 2025 | Trial primary completion date: Jun 2023 --> Jun 2025
Trial completion date • Trial primary completion date • Metastases
|
FOLH1 (Folate hydrolase 1)
|
177Lu-LNC1003
2years
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
P=N/A, N=9, Recruiting, Peking Union Medical College Hospital
New trial • Metastases
|
FOLH1 (Folate hydrolase 1)
|
FOLH1 expression • FOLH1 overexpression
|
177Lu-LNC1003
Share via
